TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15586537

Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 0
Study: 11506440

Group type: EXPERIMENTAL
Intervention: Soft contact lenses
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Rigid gas permeable (RGP) contact lenses
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: All types of lenses
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Monitoring of contact lens wear
Number of subjects: 73
Study: 9205924

Group type: COMPARATOR
Intervention: Resorbable barrier alone
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Resorbable barrier in combination with decalcified freeze-dried bone allograft (DFDBA)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Non-smokers in both treatment groups
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Resorbable barrier and DFDBA in non-smokers
Number of subjects: 14
Study: 7741850

Group type: EXPERIMENTAL
Intervention: Endoscopic biliary drainage
Number of subjects: 87

Group type: COMPARATOR
Intervention: Early elective surgery
Number of subjects: 87
Study: 3111785

Group type: EXPERIMENTAL
Intervention: Levonorgestrel 20 mcg/day IUD (LNg20)
Number of subjects: 2244

Group type: COMPARATOR
Intervention: Copper T IUD (TCu 380Ag)
Number of subjects: 2244
Study: 29563078

Group type: EXPERIMENTAL
Intervention: Overcome Social Anxiety (Web-based CBT intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 0
Study: 26149244

Group type: EXPERIMENTAL
Intervention: Cabozantinib (140 mg/day, with dose modifications allowed)
Number of subjects: 289
Study: 25634905

Group type: EXPERIMENTAL
Intervention: O-SES (sirolimus-eluting stent with biodegradable polymer)
Number of subjects: 452

Group type: COMPARATOR
Intervention: X-EES (everolimus-eluting stent with durable polymer)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: O-SES
Number of subjects: 452

Group type: COMPARATOR
Intervention: X-EES
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: O-SES (subgroup with optical coherence tomography)
Number of subjects: 452

Group type: COMPARATOR
Intervention: X-EES (subgroup with optical coherence tomography)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: O-SES (subgroup with intravascular ultrasound)
Number of subjects: 452

Group type: COMPARATOR
Intervention: X-EES (subgroup with intravascular ultrasound)
Number of subjects: 452
Study: 24185158

Group type: EXPERIMENTAL
Intervention: Behavioral intervention to increase medication adherence
Number of subjects: 0
Study: 21160310

Group type: EXPERIMENTAL
Intervention: No rectopexy
Number of subjects: 252

Group type: COMPARATOR
Intervention: Rectopexy
Number of subjects: 252
Study: 19014153

Group type: COMPARATOR
Intervention: Flap elevation (control group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Flapless procedure (test group)
Number of subjects: 20
Study: 16669842

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARBs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACE inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhibition of the renin‐angiotensin system
Number of subjects: 0
Study: 14700452

Group type: EXPERIMENTAL
Intervention: Venlafaxine extended-release (XR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bupropion sustained-release (SR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paroxetine controlled-release (CR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate-release formulations
Number of subjects: 0
Study: 11202895

Group type: EXPERIMENTAL
Intervention: 5% chlorhexidine gel
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Ledermix
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide and water
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: No medication
Number of subjects: 93
Study: 9389098

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 48

Group type: COMPARATOR
Intervention: Moxibustion
Number of subjects: 48

Group type: COMPARATOR
Intervention: Blank control group
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture vs Moxibustion
Number of subjects: 48
Study: 1483292

Group type: COMPARATOR
Intervention: Nafarelin and placebo
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Nafarelin and norethisterone 0.7 mg
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Nafarelin and norethisterone 1.4 mg
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Nafarelin and norethisterone 2.45 mg
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Nafarelin with or without norethisterone
Number of subjects: 94
Study: 2996342

Group type: EXPERIMENTAL
Intervention: Enalapril plus hydrochlorothiazide
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard triple therapy (hydrochlorothiazide, timolol, and hydralazine)
Number of subjects: 75
Study: 29631914

Group type: EXPERIMENTAL
Intervention: hTERT mRNA determination in urine
Number of subjects: 91

Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 91

Group type: COMPARATOR
Intervention: NMP22
Number of subjects: 91
Study: 27053765

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 155
Study: 24990004

Group type: EXPERIMENTAL
Intervention: Interest in providing MS care
Number of subjects: 221
Study: 22247480

Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion (3 ng/kg per minute for 1 hour) in patients with POTS
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Baseline baroreflex sensitivity in patients with POTS
Number of subjects: 15
Study: 20193079

Group type: EXPERIMENTAL
Intervention: GSK256066 87.5 mcg once per day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 18095949

Group type: EXPERIMENTAL
Intervention: Tissue angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 10328

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10328
Study: 15854871

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention designed to decrease endorsement of the thin-ideal
Number of subjects: 217

Group type: COMPARATOR
Intervention: Underweight communicator
Number of subjects: 217

Group type: COMPARATOR
Intervention: Average weight communicator
Number of subjects: 217

Group type: COMPARATOR
Intervention: Overweight communicator
Number of subjects: 217
Study: 12823383

Group type: EXPERIMENTAL
Intervention: Lifestyle and behavioural interventions (e.g., education about the prostate and bladder, avoiding caffeine, urethral milking, reassurance about prostate cancer)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Lifestyle and behavioural interventions
Number of subjects: 236
Study: 11324900

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 1 mg per day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9168853

Group type: EXPERIMENTAL
Intervention: Diskhaler inhaler
Number of subjects: 274
Study: 8467027

Group type: EXPERIMENTAL
Intervention: endotracheally administered tobramycin
Number of subjects: 69

Group type: COMPARATOR
Intervention: control group
Number of subjects: 69
Study: 2870533

Group type: EXPERIMENTAL
Intervention: dihomo‐gammalinolenic acid (DHLA) with depot neuroleptic medication
Number of subjects: 21

Group type: COMPARATOR
Intervention: placebo depot medication and DHLA capsules
Number of subjects: 21

Group type: COMPARATOR
Intervention: placebo depot medication and placebo capsules
Number of subjects: 21
Study: 28813613

Group type: EXPERIMENTAL
Intervention: Aerogen® Solo (Solo) vibrating mesh nebulizer
Number of subjects: 60

Group type: COMPARATOR
Intervention: Wright jet nebulizer
Number of subjects: 60
Study: 27358262

Group type: EXPERIMENTAL
Intervention: Nefopam 2.4 mg/ml plus fentanyl 25 µg/ml (NF group)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Fentanyl 25 µg/ml (SF group)
Number of subjects: 71
Study: 25063992

Group type: COMPARATOR
Intervention: Feedback on screening outcome and a client information leaflet (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 min of structured brief advice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 min of brief lifestyle counselling
Number of subjects: 0
Study: 23078878

Group type: EXPERIMENTAL
Intervention: Reformulated inactivated chimeric PCV1-2 vaccine (Fostera™ PCV; Pfizer Animal Health), administered as a 2.0 ml dose at 21 days of age.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-vaccinated control group (T03 and T04).
Number of subjects: 40
Study: 20515207

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral guided self-help (CBT-GSH) delivered in 8 sessions over 12 weeks by master's-level interventionists
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral guided self-help (CBT-GSH)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 123
Study: 18669816

Group type: EXPERIMENTAL
Intervention: Subcutaneous etanercept (25 mg) twice weekly
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 16433194

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg i.v. once daily for 1-4 days followed by azithromycin 500 mg orally once daily for 3 days
Number of subjects: 180

Group type: COMPARATOR
Intervention: Cefuroxime 1.5 g i.v. three times daily for 1-4 days followed by cefuroxime axetil 500 mg orally twice daily for 7 days
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 180

Group type: COMPARATOR
Intervention: Cefuroxime
Number of subjects: 180
Study: 12939210

Group type: EXPERIMENTAL
Intervention: Angioplasty (n=149)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Medical therapy (n=151)
Number of subjects: 300
Study: 12092741

Group type: EXPERIMENTAL
Intervention: Roxifiban (0.75-1.5 mg; n = 20)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Roxifiban (0.75-1.0 mg; n = 8)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Roxifiban (0.5-0.75 mg; n = 8)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Roxifiban (1.5 or 1.0 mg loading dose with or without 325 mg aspirin; n = 16)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Roxifiban (1.25-1.5 mg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (n = 5)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Roxifiban (various doses)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Roxifiban with aspirin pretreatment
Number of subjects: 52
Study: 10449977

Group type: EXPERIMENTAL
Intervention: Immunonutrition with an enteral formula enriched with arginine, omega‐3 fatty acids, and RNA (IEN group; n = 33)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Standard enteral formula (SEN; n = 35)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN; n = 32)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Immunonutrition (IEN)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Standard enteral formula (SEN)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 100
Study: 7538546

Group type: EXPERIMENTAL
Intervention: IFN-alpha
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: IFN-beta
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: IFN-gamma
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 2254557

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Aspirin therapy
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo (no treatment)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Streptokinase treatment
Number of subjects: 159
Study: 7451733

Group type: EXPERIMENTAL
Intervention: Erotic passages depicting women's sexual arousal
Number of subjects: 143

Group type: COMPARATOR
Intervention: Erotic passages depicting women's disgust
Number of subjects: 143
Study: 6436340

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 34

Group type: COMPARATOR
Intervention: Bupropion
Number of subjects: 34
Study: 28759129

Group type: EXPERIMENTAL
Intervention: Daily physical activity intervention (60 minutes daily for two school years)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Control group (curriculum-defined physical education, 45 minutes twice a week)
Number of subjects: 256
Study: 27919261

Group type: EXPERIMENTAL
Intervention: Multicomponent audit and feedback intervention
Number of subjects: 72
Study: 24504128

Group type: EXPERIMENTAL
Intervention: Computer-based vision restoration training for glaucoma (n=15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Visual discrimination placebo training (n=15)
Number of subjects: 30
Study: 23013506

Group type: EXPERIMENTAL
Intervention: 2‐mL glass tubes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2‐mL plastic tubes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 3‐mL plastic tubes
Number of subjects: 20

Group type: COMPARATOR
Intervention: 4‐mL plastic tubes
Number of subjects: 20

Group type: COMPARATOR
Intervention: 6‐mL plastic tubes
Number of subjects: 20

Group type: COMPARATOR
Intervention: 10‐mL glass tubes
Number of subjects: 20

Group type: COMPARATOR
Intervention: 10‐mL plastic tubes
Number of subjects: 20
Study: 20519876

Group type: EXPERIMENTAL
Intervention: Inhaled iloprost
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: Oral bosentan
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 1391

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1391
Study: 17118684

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg once daily
Number of subjects: 107

Group type: COMPARATOR
Intervention: Salmeterol 50 microg plus fluticasone 250 microg twice daily
Number of subjects: 107
Study: 15660766

Group type: EXPERIMENTAL
Intervention: Zonisamide 500 mg/day
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Zonisamide 300 mg/day
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Zonisamide 100 mg/day
Number of subjects: 351

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study: 14636500

Group type: EXPERIMENTAL
Intervention: Participants' perception of harmful alcohol consumption limits
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Actual alcohol consumption as recorded in medical records
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Comparison of perceived harmful limits vs actual consumption
Number of subjects: 351
Study: 11004033

Group type: EXPERIMENTAL
Intervention: 300-microg oral clonidine premedication (n = 18)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (n = 18)
Number of subjects: 36
Study: 8839320

Group type: EXPERIMENTAL
Intervention: Believers
Number of subjects: 42

Group type: COMPARATOR
Intervention: Skeptics
Number of subjects: 42
Study: 1428380

Group type: EXPERIMENTAL
Intervention: 1.2 g L-Tryptophan (L-TRY) supplementation
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 49
Study: 3930720

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HC)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Gold sodium thiomalate (GSTM)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: D-penicillamine (PEN)
Number of subjects: 72
Study: 31383537

Group type: EXPERIMENTAL
Intervention: Twin-fork-shaped miniplate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional miniplate
Number of subjects: 30
Study: 30043572

Group type: EXPERIMENTAL
Intervention: Intranasal‐jejunum nutrient canal placement using clamping pliers under gastroscope guidance
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intranasal‐jejunum nutrient canal placement using guide wire under gastroscope guidance
Number of subjects: 90
Study: 27575565

Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI) at 6.0°C ± 0.5°C for 19 minutes
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI)
Number of subjects: 8
Study: 24788875

Group type: EXPERIMENTAL
Intervention: Mobic (original product) 4 x 7.5 mg tablets
Number of subjects: 20

Group type: COMPARATOR
Intervention: Melocam (generic product) 4 x 7.5 mg tablets
Number of subjects: 20
Study: 23110267

Group type: EXPERIMENTAL
Intervention: Capsaicin cream (pain group)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo cream (control group)
Number of subjects: 26
Study: 20210618

Group type: EXPERIMENTAL
Intervention: HYR (hydrated, race trial)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: DYR (dehydrated, race trial)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: HYS (hydrated, submaximal trial)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: DYS (dehydrated, submaximal trial)
Number of subjects: 17
Study: 18450339

Group type: EXPERIMENTAL
Intervention: Participation in phase II prophylactic HIV vaccine trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recruiting strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recruitment effectiveness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recruitment methods
Number of subjects: 0
Study: 15657223

Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg thrice daily)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (usual drug treatment)
Number of subjects: 61
Study: 12819912

Group type: EXPERIMENTAL
Intervention: Epirubicin 25 mg/m² (Epi25) on a weekly intravenous regimen
Number of subjects: 79

Group type: COMPARATOR
Intervention: Epirubicin 100 mg/m² (Epi100) on a 4-weekly regimen
Number of subjects: 79
Study: 10619812

Group type: EXPERIMENTAL
Intervention: 2% lidocaine solution
Number of subjects: 156

Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 156
Study: 8780333

Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 1738173

Group type: EXPERIMENTAL
Intervention: Vitamins A, C, and E supplementation for 6 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6229707

Group type: EXPERIMENTAL
Intervention: EMG biofeedback training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 20
Study: 29813074

Group type: EXPERIMENTAL
Intervention: Placebo vaginal ring for 12 weeks (Group A)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Placebo vaginal ring for 12 weeks (Group B)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo vaginal ring (both groups)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Screening for STIs
Number of subjects: 170

Group type: COMPARATOR
Intervention: Testing for HIV
Number of subjects: 170
Study: 28381653

Group type: EXPERIMENTAL
Intervention: Hands-on learning with a bench model simulator
Number of subjects: 86

Group type: COMPARATOR
Intervention: Video-learning using an instructional video
Number of subjects: 86
Study: 25701454

Group type: EXPERIMENTAL
Intervention: Axitinib titration (5 mg twice daily during lead-in, followed by stepwise dose increases)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo titration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Axitinib titration
Number of subjects: 0
Study: 24004988

Group type: EXPERIMENTAL
Intervention: Rapid HIV testing (finger prick)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Conventional HIV serology (venepuncture)
Number of subjects: 370
Study: 21959312

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 271
Study: 18252692

Group type: EXPERIMENTAL
Intervention: azithromycin-ER (2 g single oral dose)
Number of subjects: 64

Group type: COMPARATOR
Intervention: azithromycin-IR (500 mg single oral dose)
Number of subjects: 64
Study: 16647327

Group type: EXPERIMENTAL
Intervention: Baseline leisure physical activity (PAL)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Leisure PAL at 1 year
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Leisure PAL at end of study (2 to 3 years)
Number of subjects: 274
Study: 12807332

Group type: EXPERIMENTAL
Intervention: Immediate operation
Number of subjects: 209

Group type: COMPARATOR
Intervention: 1 year waiting with orthoses
Number of subjects: 209

Group type: COMPARATOR
Intervention: 1 year waiting without orthoses
Number of subjects: 209

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 209
Study: 10824377

Group type: EXPERIMENTAL
Intervention: Teledermatology
Number of subjects: 203

Group type: COMPARATOR
Intervention: Face-to-face consultation
Number of subjects: 203
Study: 8925582

Group type: EXPERIMENTAL
Intervention: Oral L-arginine hydrochloride (5.6 to 12.6 g/d)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Matched placebo capsules
Number of subjects: 15
Study: 1507401

Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) at doses of 10, 20, or 40 mg/kg administered by 30-minute drip infusion.
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) at doses of 10 to 20 mg/kg/once, 2 to 3 times a day, maximum dose 173 mg/kg/day q.i.d.
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) in patients with purulent meningitis.
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) in patients with septicemia.
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) in patients with pneumonia.
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) in patients with UTI.
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) treatment.
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) treatment for Staphylococcus aureus.
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) treatment for Streptococcus pneumoniae.
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) treatment for Gram-positive bacteria.
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) treatment for Gram-negative bacteria.
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) treatment for Haemophilus influenzae.
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) treatment for Pseudomonas aeruginosa.
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) treatment for Escherichia coli.
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) treatment for Klebsiella pneumoniae.
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) treatment in cases with previous unsuccessful antibiotic therapies.
Number of subjects: 389
Study: 6377899

Group type: EXPERIMENTAL
Intervention: Breast stimulation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200